Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Bullboard (NDAQ:INMB)

View:
Prev 1 2
Comment by Teccingon Sep 03, 2021 3:13pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:Just the beginning

I can't think of a more exciting investment then this one. Two great prospects, cancer cure, and game changing Alzhiemer' treatment.
95
Discussion
Comment by Teccingon Aug 25, 2021 7:52pm

RE:RE:RE:RE:RE:RE:RE:RE:Just the beginning

Game changer in fighting cancer, this is excellent news, hopefully for cancer patients the FDA will expedite clinical trials so more people can have hope.
124
Discussion
Comment by Teccingon Jun 10, 2021 10:56pm

RE:RE:RE:RE:RE:RE:RE:Just the beginning

Moving in the right direction, it's when i wished added a lot more. But I don't you will need a lot, to have large pay day.
69
Discussion
Comment by Popeye82on May 01, 2021 7:37am

RE:RE:RE:RE:RE:Just the beginning

https://www.inmunebio.com/index.php/en/news-2/2021/449-muneioncnnouncesourthuarterandullear20220210304 " INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides ...more  
79
Discussion
Comment by Popeye82on Apr 27, 2021 12:32pm

RE:RE:Just the beginning

https://www.inmunebio.com/images/pdf/Presentation/2021/INMB_non-con_corp_Jan_2021.pdf
69
Discussion
Comment by Popeye82on Apr 25, 2021 5:39pm

RE:Just the beginning

https://twresearchgroup.com/2021/04/xpro1595-a-next-generation-tnf-inhibitor/
66
Discussion
Post by Marky1on Apr 16, 2021 9:32pm

Just the beginning

Great times lie ahead! 100$ is very possible...GLTA
189
Discussion
Comment by Teccingon Feb 01, 2021 10:29am

RE:So much promise

While the hot money is chase from one thing to the next, I'm only to happy to accumulate at these prices. Covid trials should be released soon, and I'm sure that it will be positive news.
67
Discussion
Post by Teccingon Jan 14, 2021 12:30am

So much promise

As a investor I'm so excited, but for people who have alzhiemer in their family, it has so much hope.
178
Discussion
Comment by Teccingon Jan 06, 2021 2:07pm

RE:RE:RE:RE:RE:RE:RE:OYAYA!

I can't be the only one out there making money on this?
68
Discussion
Comment by Teccingon Jan 05, 2021 3:26pm

RE:RE:RE:RE:RE:RE:OYAYA!

Get ready for launch, buy tickets while you can still afford them.
57
Discussion
Prev 1 2
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities